Table 2:
Drug-related adverse events by maximum grade per patient (N=54)
| Adverse Event | Bevacizumab- naïve (N=41) | Bevacizumab-prior (N=13) | ||||
|---|---|---|---|---|---|---|
| Maximum Grade | Maximum Grade | |||||
| 2 | 3 | 4 | 2 | 3 | 4 | |
| Hypertension | 5 (12%) | 16 (39%) | 1 (2%) | 4 (31%) | - | - |
| Thromboembolic events* | - | 4 (10%) | 1 (2%) | - | - | - |
| Small intestinal perforation | - | 1 (2%) | - | - | - | - |
| Anal fissure | - | 1 (2%) | - | - | - | - |
| Renal hemorrhage (arterial) | - | 1 (2%) | - | - | - | - |
| Rash acneiform | - | 1 (2%) | - | - | - | - |
| Palmar-plantar erythrodysesthesia syndrome (Hand foot syndrome) | 26 (63%) | 1 (2%) | - | 8 (62%) | - | - |
| Oral mucositis | 4 (10%) | - | - | 4 (31%) | - | - |
| Weight loss | 2 (5%) | - | - | 1 (8%) | - | - |
| Anorexia | 2 (5%) | - | - | - | - | - |
| Upper respiratory infection | 2 (5%) | - | - | - | - | |
| Diarrhea | 1 (2%) | - | - | 2 (15%) | - | - |
| Hypothyroidism | - | - | - | 2 (15%) | - | - |
| Fatigue | 1 (2%) | - | - | 1 (8%) | - | - |
| Weight gain | 1 (2%) | - | - | - | - | - |
| Nausea | 1 (2%) | - | - | - | - | - |
| Dysgeusia | 1 (2%) | |||||
| Proctitis | 1 (2%) | - | - | - | - | - |
| Pain in extremity | 1 (2%) | - | - | - | - | - |
| Peripheral sensory neuropathy | 1 (2%) | - | - | - | - | - |
| Rash maculo-papular | 1 (2%) | - | - | - | - | - |
| Urticaria | 1 (2%) | - | - | - | - | - |
| Vaginal inflammation | 1 (2%) | - | - | - | - | - |
| Labial cyst | 1 (2%) | - | - | - | - | - |
| Laboratory | ||||||
| AST increased | - | 2 (5%) | - | - | 2 (15%) | - |
| ALT increased | - | 2 (5%) | - | 1 (8%) | 1 (8%) | - |
| Hypophosphatemia | 5 (12%) | 1 (2%) | - | 1 (8%) | - | - |
| Proteinuria | 3 (7%) | - | - | 2 (15%) | - | - |
| Lipase increased | 3 (7%) | - | - | 1 (8%) | - | - |
| Amylase increased | 1 (2%) | - | - | 1 (8%) | - | - |
| Bilirubin increased | - | - | - | 1 (8%) | - | - |
*
Two patients developed right neck jugular vein clots related to the catheter, and three developed grade 3 deep vein thrombosis and pulmonary embolism (PE) (n=2) and grade 4 PE (n=1).